ZIM
OMGA

Zacks Investment Management’s Omega Therapeutics, Inc. Common Stock OMGA Stock Holding History

Zacks Investment Management’s Portfolio OMGA Stock Details OMGA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-306,426
Closed -$922K – 725
2023
Q4 		$922K Buy
+306,426
New +$621K 0.01% 388

Other funds holding OMGA

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Zacks Investment Management's OMGA Position: Q1 2024 in Review

Zacks Investment Management sold out of Omega Therapeutics, Inc. Common Stock (OMGA) in Q1 2024, closing a stake of 306,426 shares — an estimated $922K sold.

Zacks Investment Management first reported a position in OMGA in Q4 2023 and held it in 1 quarter. The position peaked at $922K in Q4 2023. 70 funds tracked by Wall St. Rank hold OMGA as of Q1 2024.

  • Zacks Investment Management reported no remaining Omega Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Zacks Investment Management sold 306,426 Omega Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $922K.
  • Zacks Investment Management first reported a position in Omega Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Zacks Investment Management's Omega Therapeutics, Inc. Common Stock position peaked at $922K in Q4 2023.
  • 70 funds tracked by Wall St. Rank held Omega Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Zacks Investment Management's 13F filing for Q1 2024, filed 15 May 2024.